title: Does interferon use prior to liver transplant influence hepatitis C outcomes following transplantation?
abstract: BACKGROUND
  The most frequent reason for orthotopic liver transplantation (OLT) in the United States is due to complications of hepatitis C (HCV). Recent reports have shown decreased survival for HCV after OLT. Of note, the use of interferon (IFN) products has become wide spread with the majority of HCV patients being treated before transplant.
  
  
  OBJECTIVE
  To review the outcomes of HCV patients who have received IFN products before liver transplant compared with HCV patients those who have never received IFN.
  
  
  METHODS
  Single-center, retrospective review of patients transplanted for HCV since December 1998 (n=131). Primary endpoint is the effect of IFN exposure before transplant on posttransplant outcomes.
  
  
  RESULTS
  Patients receiving before transplant (pre-IFN group; n=45) had a more aggressive recurrence of HCV with earlier recurrence (181.1+/-236 days vs. 303.4+/- 327 days; P=0.031), frequency of recurrence [41/45 (91.1%) vs. 62/86 (72.1%); P=0.013], and 1-year recurrence free survival [20% (+/-0.06) vs. 48.2% (+/-0.05); P=0.005]. Survival difference was noted in the pre-IFN group at 1 year and 3 years [79.7% (+/-0.06) vs. 90.5% (+/-0.03); 65.7 (+/-0.08) vs. 75.9% (+/-0.05); P=0.05] when compared with patients not receiving IFN (n=86) before transplant.
  
  
  CONCLUSIONS
  Based on this study, interferon use before transplant for the HCV patient indicates poor outcomes After OLT. Because of the increasing numbers of HCV patients coming to transplant, validation of these results should be of utmost importance.
authors.affiliation: Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Smallwood
authors.forename: Renee
authors.initials: R
authors.lastname: Devine
authors.forename: Carlos
authors.initials: C
authors.lastname: Fasola
authors.forename: Andrei C
authors.initials: AC
authors.lastname: Stieber
authors.forename: Thomas G
authors.initials: TG
authors.lastname: Heffron
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000077561:Daclizumab; D018572:Disease-Free Survival; D005260:Female; D006526:Hepatitis C / Q000188:drug therapy* / Q000601:surgery*; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000601:surgery; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007372:Interferons / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000401:mortality / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D044469:Racial Groups / Q000706:statistics & numerical data; D012008:Recurrence; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D007372:Interferons; D000077561:Daclizumab